American Association for Cancer Research 100th Annual Meeting.
Carlson
Robert H
RH
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D012106:Research / Q000639:trends*; D012955:Societies, Medical; D014481:United States; D000077337:Vorinostat
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000068258:Bevacizumab; D000077337:Vorinostat; D000069347:Erlotinib Hydrochloride